Skip to main content

Table 1 Clinical characteristics and areal BMD of AS patients and non-AS subjects

From: Alterations of bone mineral density, bone microarchitecture and strength in patients with ankylosing spondylitis: a cross-sectional study using high-resolution peripheral quantitative computerized tomography and finite element analysis

Variable AS patients Non-AS subjects
Number 53 85
Men (%) 29 (55)* 25 (29)
Caucasians 40 (75)* 76 (89)
Age (years) 44 ± 12* 61 ± 8
Weight (kg) 75 ± 3 76 ± 2
Height (cm) 167 ± 2 164 ± 1
BMI (kg/m2) 27 (22–32) 27 (25–31)
Fragility fractures (%) 5 (9) 6 (11)
Corticosteroid use (%) 3 (6) 5 (6)
Bisphosphonate use (%) 4 (9) 13 (15)
DMARDs (%) 7 (13) 0 (0)
Total daily calcium intake (mg) 745 (456–1020)* 1045 (471–1539)
Use of supplemental vitamin D (%)a 19 (36) 32 (38)
Hormone therapy (%)b 0 (0)* 16 (19)
Areal BMDc (g/cm2)   
 L1–L4 0.994 ± 0.179 0.988 ± 0.156
 Total hip 0.904 ± 0.149 0.930 ± 0.123
 Femoral neck 0.767 ± 0.142 0.756 ± 0.116
 Distal 1/3 radius 0.740 ± 0.127 0.644 ± 0.170
 Ultra distal radius 0.477 ± 0.078 0.418 ± 0.120
 Low BMD/osteopenia (%) 18 (34) 37 (44)
 Osteoporosis (%) 6 (11) 7 (8)
  1. Data expressed as mean ± standard deviation, median (interquartile range) or number (% N) unless specified otherwise
  2. aAt least 1000 IU vitamin D
  3. bPostmenopausal women receiving hormone replacement treatment
  4. cIntergroup comparison of BMD was not performed between AS and non-AS subjects because of the differences in age and sex
  5. *p <0.05
  6. AS ankylosing spondylitis, BMD bone mineral density, BMI body mass index, DMARD disease-modifying antirheumatic drug
\